There's no reason people should be dying from cancer today, especially since we've invented a powerful new technology that will usher in a new wave of treatments that can cure cancer.
The biggest problem in cancer remains resistance to chemotherapy and loss of response to treatment which leaves patients with no viable options. The cells that are the most resistant are the tumor propagating cells, and current therapies have failed at a cure. So instead of trying to kill these cancer cells, we are inducing them to differentiate into normal cells that are non-tumorigenic.
We have tackled this problem by utilizing epigenetics and live imaging to identify novel therapeutics that induce the differentiation of tumor propagating cells into non-tumorigenic cells instead of trying to kill them. Our approach is amenable to high throughput screening (HTS) of small molecule libraries; it is universal and applicable to many tumor types and developmental diseases such as Huntington's; it is 30 times more cost effective than conventional sequencing; it's very fast, we can screen 1 million compounds in less than a year; and most importantly, the robustness of epigenetics to identify novel targets and therapeutics that can be used to treat cancer and neurodegenerative diseases such as Huntington's and Alzheimer's, are not feasible with other approaches. The core of our technology is cell identity; we can visually see the difference between a cancer cell and a normal cell on the path towards differentiation. Thus, we can obtain readouts that are not possible with other approaches.
My Mom had breast cancer and stopped responding to chemotherapy and five weeks later she died at our home where we were looking after her. My Dad died two years later from pancreatic cancer and prostate cancer. I worked for one of the world's largest drug companies for 15 years and I couldn't help them.
My wife's Mom died of ovarian cancer when she was 11 years old. Back then, the visiting hours for hospitals were different than they are now and she died in the hospital when her family were at home. I have a tremendous amount of respect for her Dad, who raised the family on his own. He also died of cancer a few years ago.
After these personal experiences within my own family, I knew my purpose was to create positive change in the world and become a fighter for cancer patients. My passion is to create a better future for our kids.
It's the people that make the difference. One commonality we have is the shared mission of delivering medicines of value to the patients that need them. JLABS has created a capital efficient no strings attached business model that enables innovation. We couldn't bring our breakthrough idea to patients without the support and encouragement of the people at JLABS.
Meet the Team:
Attila Hajdu, MBA, MSc, Chief Executive Officer
Alexey Terskikh, PhD, Chief Scientific Officer